EICHORCondition: Primary Open Angle Glaucoma (POAG) · Primary Open Angle Glaucoma of Both Eyes · Primary Open-Angle Glaucoma, Unspecified Eye · Sponsor: Qlaris Bio, Inc.
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * 18 years or older * Able to provide written acknowledgement of giving informed consent * Best corrected visual acuity (BCVA) 20/200 or better Bilateral POAG or OHT with documented historic IOP value(s) ≥24 mmHg, in either eye * Post-washout IOP ≥22 mmHg in morning on Visits 2 and 3 and ≥18 mmHg at noon on Visit 2 Exclusion Criteria: * IOP \>34 mmHg * Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications * Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study) * Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye * Use of other ophthalmic concomitant medications during the study * Uncontrolled hypertension or hypotension * Significant systemic or psychiatric disease * Participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product * Pregnant or lactating
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Coastal Research Associates, LLC | Roswell, Georgia, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016972